ATAI Life Sciences N.V. Common Shares ATAI

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    -$0.07 (-4.46%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of ATAI Life Sciences N.V. Common Shares (ATAI)
    ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $1.51

    • Market Cap

      $292.93 Million

    • Price-Earnings Ratio

      -1.89

    • Total Outstanding Shares

      193.99 Million Shares

    • Total Employees

      83

    • Dividend

      No dividend

    • IPO Date

      June 18, 2021

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      Wallstrasse 16, Berlin, 2M, 10179

    • Homepage

      https://www.atai.life

    Historical Stock Splits

    Execution DateSplit Amount
    No Historical Stock Splits

    Cash Flow Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Net Cash Flow From Operating Activities, Continuing$-80.10 Million
    Net Cash Flow From Operating Activities$-80.10 Million
    Net Cash Flow$-31.56 Million
    Net Cash Flow From Investing Activities, Continuing$51.79 Million
    Net Cash Flow From Financing Activities$-3.24 Million
    Net Cash Flow From Financing Activities, Continuing$-3.24 Million

    Income Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Net Income/Loss Available To Common Stockholders, Basic$-128.60 Million
    Income/Loss From Equity Method Investments$-2.39 Million
    Operating Expenses$106.32 Million
    Benefits Costs and Expenses$127.87 Million
    Income/Loss From Continuing Operations Before Tax$-127.54 Million
    Income/Loss From Continuing Operations After Tax$-127.81 Million

    Comprehensive Income

    October 1, 2023 to September 30, 2024
    MetricValue
    Comprehensive Income/Loss$-131.25 Million
    Comprehensive Income/Loss Attributable To Parent$-129.61 Million
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$-1.64 Million
    Other Comprehensive Income/Loss$-1.05 Million

    Balance Sheet

    October 1, 2023 to September 30, 2024
    MetricValue
    Assets$197.52 Million
    Fixed Assets$865,000
    Equity Attributable To Noncontrolling Interest$596,000
    Liabilities And Equity$197.52 Million
    Current Liabilities$19.64 Million
    Equity Attributable To Parent$145.72 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about ATAI from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.